This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Alvesco

Sumitomo Dainippon Pharma Co., Ltd.

Drug Names(s): ciclesonide

Description: Alvesco is an inhaled corticosteroid, initially developed for once-daily use, but currently recommended in the US for twice-daily use. It is a pro-drug that is converted into its active form in the body. Alvesco is delivered via an HFA MDI.

Deal Structure: Aventis Pharmaceuticals and Byk Gulden, the pharmaceutical group of ALTANA AG, signed an agreement in March 2001 pertaining to Byk Gulden's new inhaled corticosteroid, ciclesonide, for the treatment of asthma. Under the terms of the agreement, both companies will jointly develop and promote ciclesonide in the United States. No financial terms were disclosed. In December 2006, Nycomed acquired Altana Pharma and its developmental compounds.

In April 2007, As part of the agreements with Altana Pharma (member of the Nycomed group) concerning Alvesco in the US, Sanofi aventis has informed its partner of its decision to transfer back its rights related to Alvesco.

In January 2008, Nycomed granted Sepracor the exclusive development, marketing and commercialisation rights for Ciclesonide in the United States. Nycomed will receive an upfront payment of $150 million and subsequent payments upon accomplishment of various development and sales milestones, which could include up to an...See full deal structure in Biomedtracker

Partners: Teijin Pharma Limited AstraZeneca PLC


Alvesco News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug